Cargando…

Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients

Long non-coding RNAs are defined as transcripts larger than 200 nucleotides but without protein-coding potential. There is growing evidence of the important role of long non-coding RNAs in cancer initiation, development and progression. In this study, we sought to evaluate the long non-coding RNA ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Clara, Etienne, Gourvest, Morgane, Ma, Hanjing, Vergez, François, Tosolini, Marie, Dejean, Sébastien, Demur, Cécile, Delabesse, Eric, Recher, Christian, Touriol, Christian, Martelli, Maria Paola, Falini, Brunangelo, Brousset, Pierre, Bousquet, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622856/ https://www.ncbi.nlm.nih.gov/pubmed/28679652 http://dx.doi.org/10.3324/haematol.2017.171645

Ejemplares similares

A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA
por: Gourvest, Morgane, et al.
Publicado: (2021)

Long Noncoding RNAs in Acute Myeloid Leukemia: Functional Characterization and Clinical Relevance
por: Gourvest, Morgane, et al.
Publicado: (2019)

Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field
por: Falini, Brunangelo, et al.
Publicado: (2021)

A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML)
por: Venanzi, Alessandra, et al.
Publicado: (2021)

The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein
por: Pianigiani, Giulia, et al.
Publicado: (2022)

IDH1-R132 changes vary according to NPM1 and other mutations status in AML
por: Falini, Brunangelo, et al.
Publicado: (2019)

PB1762: A NEW MONOCLONAL ANTIBODY PROVIDES INSIGHTS ON NPM1 MUTANT SUBCELLULAR EXPRESSION, INTRACLONAL CELL DIFFERENTIATION AND MRD IN NPM1-MUTATED AML
por: Falini, Brunangelo, et al.
Publicado: (2023)

Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia
por: Forghieri, Fabio, et al.
Publicado: (2019)

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2015)

Current status and future perspectives in targeted therapy of NPM1-mutated AML
por: Ranieri, Roberta, et al.
Publicado: (2022)

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
por: Perriello, Vincenzo Maria, et al.
Publicado: (2021)

NPM1 Deletion Is Associated with Gross Chromosomal Rearrangements in Leukemia
por: La Starza, Roberta, et al.
Publicado: (2010)

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
por: Devillier, Raynier, et al.
Publicado: (2015)

Vitamin C and D supplementation in acute myeloid leukemia
por: Mouchel, Pierre Luc, et al.
Publicado: (2023)

A case of cup‐like blasts associated with B‐lymphoblastic leukemia without NPM1 and FLT3 internal tandem duplication mutations
por: Rieu, Jean‐Baptiste, et al.
Publicado: (2020)

Genomic landscape of hyperleukocytic acute myeloid leukemia
por: Largeaud, Laetitia, et al.
Publicado: (2022)

GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
por: Sportoletti, Paolo, et al.
Publicado: (2019)

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience
por: LaRochelle, Olivier, et al.
Publicado: (2011)

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
por: Pianigiani, Giulia, et al.
Publicado: (2022)

The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics
por: How, J, et al.
Publicado: (2013)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation
por: Garciaz, Sylvain, et al.
Publicado: (2019)

Dexamethasone in hyperleukocytic acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2018)

CD34(+)CD38(−)CD123(+) Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents
por: Vergez, François, et al.
Publicado: (2020)

All‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with NPM1‐mutated AML unfit for intensive chemotherapy and review of the literature
por: Forghieri, Fabio, et al.
Publicado: (2016)

Generation of the first monoclonal antibody using mouse hybridomas
por: Falini, Brunangelo
Publicado: (2022)

Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML
por: Gionfriddo, Ilaria, et al.
Publicado: (2021)

FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia
por: Sorcini, D, et al.
Publicado: (2023)

MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status
por: Faraoni, Isabella, et al.
Publicado: (2012)

P519: RISK STRATIFICATION BY NOMOGRAM SCORING SYSTEM OF NPM1-MUTATED CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIALEUKAEMIA BASED ON A MULTI-GENE PANEL
por: Zhao, Mingyue, et al.
Publicado: (2023)

Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia
por: Chen, Yingyu, et al.
Publicado: (2020)

The frequency of NPM1 mutations in childhood acute myeloid leukemia
por: Braoudaki, Maria, et al.
Publicado: (2010)

Colonic myeloid sarcoma with mutated NPM1 manifesting with ulceration
por: Tashakori, Mehrnoosh, et al.
Publicado: (2022)

Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use
por: Lesieur, Auriane, et al.
Publicado: (2020)

Clinical Implications of Inflammation in Acute Myeloid Leukemia
por: Récher, Christian
Publicado: (2021)

Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML
por: Diaz de la Guardia, Rafael, et al.
Publicado: (2020)

Optical Imaging of Disseminated Leukemia Models in Mice with Near-Infrared Probe Conjugated to a Monoclonal Antibody
por: Pesnel, Sabrina, et al.
Publicado: (2012)

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience
por: Bertoli, Sarah, et al.
Publicado: (2019)

ARPIR: automatic RNA-Seq pipelines with interactive report
por: Spinozzi, Giulio, et al.
Publicado: (2020)

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML
por: Martelli, Maria Paola, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mkca131gcvqvrefo2vhqlhujou